Mostrar el registro sencillo del ítem

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada.

dc.rights.licenseopenen_US
dc.contributor.authorRUIZ-BURGA, Elisa
dc.contributor.authorTARIQ, Shema
dc.contributor.authorTOULOUMI, Giota
dc.contributor.authorGILL, John
dc.contributor.authorNICHOLLS, Emily Jay
dc.contributor.authorSABIN, Caroline
dc.contributor.authorMUSSINI, Cristina
dc.contributor.authorMEYER, Laurence
dc.contributor.authorVOLNY ANNE, Alain
dc.contributor.authorCARLANDER, Christina
dc.contributor.authorGRABAR, Sophie
dc.contributor.authorJARRIN, Inma
dc.contributor.authorVAN DER VALK, Marc
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorSPIRE, Bruno
dc.contributor.authorPANTAZIS, Nikos
dc.contributor.authorBURNS, Fiona M
dc.contributor.authorPORTER, Kholoud
dc.date.accessioned2023-09-15T08:57:54Z
dc.date.available2023-09-15T08:57:54Z
dc.date.issued2023-05-11
dc.identifier.issn2044-6055en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/183682
dc.description.abstractEnDespite the availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), 21 793 people were newly diagnosed with HIV in Europe in 2019. The Concerted action on seroconversion to AIDS and death in Europe study aims to understand current drivers of the HIV epidemic; factors associated with access to, and uptake of prevention methods and ART initiation; and the experiences, needs and outcomes of people with recently acquired HIV. This longitudinal observational study is recruiting participants aged ≥16 years with documented laboratory evidence of HIV seroconversion from clinics in Canada and six European countries. We will analyse data from medical records, self-administered questionnaires, semistructured interviews and participatory photography. We will assess temporal trends in transmitted drug resistance and viral subtype and examine outcomes following early ART initiation. We will investigate patient-reported outcomes, well-being, and experiences of, knowledge of, and attitudes to HIV preventions, including PrEP. We will analyse qualitative data thematically and triangulate quantitative and qualitative findings. As patient public involvement is central to this work, we have convened a community advisory board (CAB) comprising people living with HIV. All respective research ethics committees have approval for data to contribute to international collaborations. Written informed consent is required to take part. A dissemination strategy will be developed in collaboration with CAB and the scientific committee. It will include peer-reviewed publications, conference presentations and accessible summaries of findings on the study's website, social media and via community organisations.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enHumans
dc.subject.enHIV Infections
dc.subject.enAcquired Immunodeficiency Syndrome
dc.subject.enCanada
dc.subject.enEurope
dc.subject.enPre-Exposure Prophylaxis
dc.subject.enPatient Reported Outcome Measures
dc.subject.enObservational Studies as Topic
dc.subject.enMulticenter Studies as Topic
dc.title.enCASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada.
dc.title.alternativeBMJ Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/bmjopen-2022-070837en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37169505en_US
bordeaux.journalBMJ Openen_US
bordeaux.pagee070837en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue5en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDViiV Healthcareen_US
bordeaux.identifier.funderIDJanssen Pharmaceuticalsen_US
bordeaux.identifier.funderIDMerck Sharp and Dohmeen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMJ%20Open&rft.date=2023-05-11&rft.volume=13&rft.issue=5&rft.spage=e070837&rft.epage=e070837&rft.eissn=2044-6055&rft.issn=2044-6055&rft.au=RUIZ-BURGA,%20Elisa&TARIQ,%20Shema&TOULOUMI,%20Giota&GILL,%20John&NICHOLLS,%20Emily%20Jay&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_BMJ Open_2023_Ruiz-Burga.pdf
Tamaño:
395.3Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
920bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem